Innate Pharma Stock (NASDAQ:IPHA)
Previous Close
$2.33
52W Range
$1.81 - $3.15
50D Avg
$2.18
200D Avg
$2.47
Market Cap
$186.99M
Avg Vol (3M)
$7.09K
Beta
0.79
Div Yield
-
IPHA Company Profile
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
IPHA Performance
Peer Comparison
Ticker | Company |
---|---|
CYT | Cyteir Therapeutics, Inc. |
DYAI | Dyadic International, Inc. |
IPSC | Century Therapeutics, Inc. |
INBX | Inhibrx, Inc. |
CSBR | Champions Oncology, Inc. |
HCWB | HCW Biologics Inc. |
MNOV | MediciNova, Inc. |
ANEB | Anebulo Pharmaceuticals, Inc. |
MOLN | Molecular Partners AG |
ADXN | Addex Therapeutics Ltd |
PRDS | Pardes Biosciences, Inc. |
STTK | Shattuck Labs, Inc. |
ELYM | Eliem Therapeutics, Inc. |